Emerging data suggest Retatru tide , a dual agonist targeting both incretin and glucose-dependent insulinotropic polypeptide , could provide a significant advancement for weight management . Preliminary clinical tests have demonstrated considerable decreases in visceral fat , conceivably surpassing other weight-loss treatments. However , more study